Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01367613 | Open-Label Treatment Extension of Protocol MNTX 302 | PHASE3 | COMPLETED | 89 | — | — | Mar 1, 2004 | Jan 1, 2006 | Nov 27, 2019 | 1 | United States |
| NCT01367600 | Open-Label Treatment Extension of Protocol MNTX 301 | PHASE3 | COMPLETED | 27 | — | — | Feb 1, 2003 | Feb 1, 2005 | Nov 27, 2019 | 1 | United States |
To provide access to treatment with MNTX, administered SC, to patients who completed Progenics' Protocol MNTX 302
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SC Methylnaltrexone | DRUG | - |
| SC Methylnaltrexone (MNTX) | DRUG | - |
Inclusion Criteria: 1. Must be enrolled and consented within 28 days of the end of study visit of MNTX 302 and 14 or more days from first dose of study drug in MNTX 302. 2. Negative pregnancy test 3. Stable vital signs Exclusion Criteria: 1. Women who are pregnant and/or nursing 2. Received any i...